# US 2012/0252750 A1 · Formulations for reducing neuronal degeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252750 A1
- Document ID: US20120252750A1
- Status: Published application
- Kind: A1
- Application number: 13/437,487
- Filed: 2012-04-02
- Published: 2012-10-04
- Earliest claimed: 2003-07-25
- Assignees: University of Massachusetts
- Inventors: Thomas B. SHEA; Robert J. NICOLOSI; Eugene ROGERS
- Web page: https://patentgrep.com/patent/US20120252750A1

## CPC

- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A23L 33/15: Vitamins
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer's disease are provided. Nutriceutical formulations include two or more of folate, vitamin E, and acetyl-L-carnitine (ALCAR). Pharmaceutical formulations include two or more of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM).

## Claims

### Claim 1

A method for treating a neurodegenerative disorder in a mammal, the method comprising administering to the mammal an amount of a formulation effective to reduce a level of reactive oxygen species (ROS) in an in vitro neural cell culture, wherein the formulation comprises, folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms.

### Claim 2 (depends on 1)

The method of claim 1, wherein the formulation comprises folate, vitamin E, ALCAR, NAC, and SAM.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mammal suffers from a neurodegenerative disorder selected from the group consisting of Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis (ALS).

### Claim 4 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 5 (depends on 1)

The method of claim 1, wherein a level of reactive oxygen species (ROS) in the mammal is reduced compared to a reference.

### Claim 6

A composition comprising, folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms, wherein a unit dose of the composition reduces a level of reactive oxygen species (ROS) in an in vitro neural cell culture.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the composition comprises folate, vitamin E, ALCAR, NAC, and SAM.

### Claim at position 8

8-25. (canceled)

### Claim 26 (depends on 6)

The composition of claim 6, wherein the unit dose comprises about 200-2000 μg folate.

### Claim 27 (depends on 6)

The composition of claim 6, wherein the unit dose comprises about 50-3000 I.U. vitamin E.

### Claim 28 (depends on 6)

The composition of claim 6, wherein the unit dose comprises about 200-4000 mg ALCAR.

### Claim 29 (depends on 6)

The composition of claim 6, wherein the unit dose comprises about 200-2000 mg NAC.

### Claim 30 (depends on 6)

The composition of claim 6, wherein the unit dose comprises about 400-2000 mg SAM.

### Claim 31 (depends on 6)

The composition of claim 6, wherein the unit dose comprises about 20-500 mg DZA.

### Claim 32 (depends on 7)

The composition of claim 7, wherein the unit dose comprises about 200-2000 μg folate, about 50-3000 I.U. vitamin E, about 200-4000 mg ALCAR, about 200-2000 mg NAC, and about 400-2000 mg SAM.

### Claim 33 (depends on 7)

The composition of claim 7, wherein the unit dose comprises about 400-1500 μg folate, about 50 I.U. vitamin E, about 500-3000 mg ALCAR, about 500-1500 mg NAC, and about 400-1500 mg SAM.

### Claim 34 (depends on 7)

The composition of claim 7, wherein the unit dose of the composition comprises about 200-2000 μg folate, about 200-4000 mg ALCAR, about 400-2000 mg SAM, and about 200-2000 mg NAC.

### Claim 35 (depends on 7)

The composition of claim 7, wherein the unit dose of the composition comprises about 400-1500 μg folate, about 500-3000 mg ALCAR, about 400-1500 mg SAM, and about 500-1500 mg NAC.

### Claim 36

A composition comprising folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms, wherein a unit dose of the composition improves memory in a subject.

### Claim 37 (depends on 6, 7)

A method of improving memory in a subject, comprising administering a composition of any one of claim 6, 7, or 26-35 to the subject, such that memory is improved.
